Global Point of Care (POC) Molecular Diagnostics Market to Reach $5.2 Billion by 2027

Abstract: - Global Point of Care (POC) Molecular Diagnostics Market to Reach $5. 2 Billion by 2027. - Amid the COVID-19 crisis, the global market for Point of Care (POC) Molecular Diagnostics estimated at US$2.

New York, July 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Point of Care (POC) Molecular Diagnostics Industry" - https://www.reportlinker.com/p06032550/?utm_source=GNW
2 Billion in the year 2020, is projected to reach a revised size of US$5.2 Billion by 2027, growing at a CAGR of 13.2% over the analysis period 2020-2027. PCR-based, one of the segments analyzed in the report, is projected to record a 14.3% CAGR and reach US$2.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Genetic Sequencing-based segment is readjusted to a revised 12% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $590.9 Million, While China is Forecast to Grow at 17.3% CAGR
- The Point of Care (POC) Molecular Diagnostics market in the U.S. is estimated at US$590.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2027 trailing a CAGR of 17.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.2% and 11.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.
- Hybridization-based Segment to Record 13.3% CAGR
- In the global Hybridization-based segment, USA, Canada, Japan, China and Europe will drive the 12.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$279.2 Million in the year 2020 will reach a projected size of US$635.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$776.7 Million by the year 2027, while Latin America will expand at a 14.9% CAGR through the analysis period.

- Select Competitors (Total 33 Featured) -

• Abaxis Inc.

• Abbott Laboratories

• BioMérieux SA

• Bio-Rad Laboratories

• Danaher Corporation

• F. Hoffmann-La Roche, Ltd.

• Meridian biosciences

• Mesa Biotech

• Quidel

• Siemens Healthcare GmbH

• Sysmex Corporation

• Vircell S.L

Read the full report: https://www.reportlinker.com/p06032550/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Point of Care (POC)
Molecular Diagnostics by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for PCR-based by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for PCR-based by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for PCR-based by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Genetic
Sequencing-based by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Genetic Sequencing-based by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Genetic Sequencing-based
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for
Hybridization-based by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Hybridization-based by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Hybridization-based by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Microarray-based
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Microarray-based by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Microarray-based by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Decentralized
Labs by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Decentralized Labs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Decentralized Labs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Home Care by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Home Care by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Home Care by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Assisted Living
Healthcare Facilities by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Assisted Living Healthcare
Facilities by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Assisted Living
Healthcare Facilities by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 28: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 29: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Infectious
Diseases by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Infectious Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Infectious Diseases by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 35: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 36: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Hematology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 38: World Historic Review for Hematology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 39: World 15-Year Perspective for Hematology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 40: World Current & Future Analysis for Prenatal Testing
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 41: World Historic Review for Prenatal Testing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 42: World 15-Year Perspective for Prenatal Testing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 43: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 44: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 45: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 46: USA Current & Future Analysis for Point of Care (POC)
Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 47: USA Historic Review for Point of Care (POC) Molecular
Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 48: USA 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Technology - Percentage Breakdown of
Value Sales for PCR-based, Genetic Sequencing-based,
Hybridization-based and Microarray-based for the Years 2012,
2020 & 2027

Table 49: USA Current & Future Analysis for Point of Care (POC)
Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 50: USA Historic Review for Point of Care (POC) Molecular
Diagnostics by End-Use - Decentralized Labs, Hospitals, Home
Care, Assisted Living Healthcare Facilities and Other End-Uses
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 51: USA 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by End-Use - Percentage Breakdown of
Value Sales for Decentralized Labs, Hospitals, Home Care,
Assisted Living Healthcare Facilities and Other End-Uses for
the Years 2012, 2020 & 2027

Table 52: USA Current & Future Analysis for Point of Care (POC)
Molecular Diagnostics by Application - Infectious Diseases,
Oncology, Hematology, Prenatal Testing and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 53: USA Historic Review for Point of Care (POC) Molecular
Diagnostics by Application - Infectious Diseases, Oncology,
Hematology, Prenatal Testing and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 54: USA 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Application - Percentage Breakdown of
Value Sales for Infectious Diseases, Oncology, Hematology,
Prenatal Testing and Other Applications for the Years 2012,
2020 & 2027

CANADA
Table 55: Canada Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 56: Canada Historic Review for Point of Care (POC)
Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 57: Canada 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Technology - Percentage Breakdown of
Value Sales for PCR-based, Genetic Sequencing-based,
Hybridization-based and Microarray-based for the Years 2012,
2020 & 2027

Table 58: Canada Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 59: Canada Historic Review for Point of Care (POC)
Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: Canada 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by End-Use - Percentage Breakdown of
Value Sales for Decentralized Labs, Hospitals, Home Care,
Assisted Living Healthcare Facilities and Other End-Uses for
the Years 2012, 2020 & 2027

Table 61: Canada Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Application - Infectious
Diseases, Oncology, Hematology, Prenatal Testing and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 62: Canada Historic Review for Point of Care (POC)
Molecular Diagnostics by Application - Infectious Diseases,
Oncology, Hematology, Prenatal Testing and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 63: Canada 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Application - Percentage Breakdown of
Value Sales for Infectious Diseases, Oncology, Hematology,
Prenatal Testing and Other Applications for the Years 2012,
2020 & 2027

JAPAN
Table 64: Japan Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for Point of Care (POC)
Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 66: Japan 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Technology - Percentage Breakdown of
Value Sales for PCR-based, Genetic Sequencing-based,
Hybridization-based and Microarray-based for the Years 2012,
2020 & 2027

Table 67: Japan Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 68: Japan Historic Review for Point of Care (POC)
Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: Japan 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by End-Use - Percentage Breakdown of
Value Sales for Decentralized Labs, Hospitals, Home Care,
Assisted Living Healthcare Facilities and Other End-Uses for
the Years 2012, 2020 & 2027

Table 70: Japan Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Application - Infectious
Diseases, Oncology, Hematology, Prenatal Testing and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 71: Japan Historic Review for Point of Care (POC)
Molecular Diagnostics by Application - Infectious Diseases,
Oncology, Hematology, Prenatal Testing and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 72: Japan 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Application - Percentage Breakdown of
Value Sales for Infectious Diseases, Oncology, Hematology,
Prenatal Testing and Other Applications for the Years 2012,
2020 & 2027

CHINA
Table 73: China Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 74: China Historic Review for Point of Care (POC)
Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 75: China 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Technology - Percentage Breakdown of
Value Sales for PCR-based, Genetic Sequencing-based,
Hybridization-based and Microarray-based for the Years 2012,
2020 & 2027

Table 76: China Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 77: China Historic Review for Point of Care (POC)
Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 78: China 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by End-Use - Percentage Breakdown of
Value Sales for Decentralized Labs, Hospitals, Home Care,
Assisted Living Healthcare Facilities and Other End-Uses for
the Years 2012, 2020 & 2027

Table 79: China Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Application - Infectious
Diseases, Oncology, Hematology, Prenatal Testing and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 80: China Historic Review for Point of Care (POC)
Molecular Diagnostics by Application - Infectious Diseases,
Oncology, Hematology, Prenatal Testing and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 81: China 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Application - Percentage Breakdown of
Value Sales for Infectious Diseases, Oncology, Hematology,
Prenatal Testing and Other Applications for the Years 2012,
2020 & 2027

EUROPE
Table 82: Europe Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Point of Care (POC)
Molecular Diagnostics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 85: Europe Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 86: Europe Historic Review for Point of Care (POC)
Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 87: Europe 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Technology - Percentage Breakdown of
Value Sales for PCR-based, Genetic Sequencing-based,
Hybridization-based and Microarray-based for the Years 2012,
2020 & 2027

Table 88: Europe Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 89: Europe Historic Review for Point of Care (POC)
Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 90: Europe 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by End-Use - Percentage Breakdown of
Value Sales for Decentralized Labs, Hospitals, Home Care,
Assisted Living Healthcare Facilities and Other End-Uses for
the Years 2012, 2020 & 2027

Table 91: Europe Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Application - Infectious
Diseases, Oncology, Hematology, Prenatal Testing and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 92: Europe Historic Review for Point of Care (POC)
Molecular Diagnostics by Application - Infectious Diseases,
Oncology, Hematology, Prenatal Testing and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 93: Europe 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Application - Percentage Breakdown of
Value Sales for Infectious Diseases, Oncology, Hematology,
Prenatal Testing and Other Applications for the Years 2012,
2020 & 2027

FRANCE
Table 94: France Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 95: France Historic Review for Point of Care (POC)
Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 96: France 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Technology - Percentage Breakdown of
Value Sales for PCR-based, Genetic Sequencing-based,
Hybridization-based and Microarray-based for the Years 2012,
2020 & 2027

Table 97: France Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 98: France Historic Review for Point of Care (POC)
Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 99: France 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by End-Use - Percentage Breakdown of
Value Sales for Decentralized Labs, Hospitals, Home Care,
Assisted Living Healthcare Facilities and Other End-Uses for
the Years 2012, 2020 & 2027

Table 100: France Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Application - Infectious
Diseases, Oncology, Hematology, Prenatal Testing and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 101: France Historic Review for Point of Care (POC)
Molecular Diagnostics by Application - Infectious Diseases,
Oncology, Hematology, Prenatal Testing and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 102: France 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Application - Percentage Breakdown of
Value Sales for Infectious Diseases, Oncology, Hematology,
Prenatal Testing and Other Applications for the Years 2012,
2020 & 2027

GERMANY
Table 103: Germany Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 104: Germany Historic Review for Point of Care (POC)
Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 105: Germany 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Technology - Percentage Breakdown of
Value Sales for PCR-based, Genetic Sequencing-based,
Hybridization-based and Microarray-based for the Years 2012,
2020 & 2027

Table 106: Germany Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 107: Germany Historic Review for Point of Care (POC)
Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 108: Germany 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by End-Use - Percentage Breakdown of
Value Sales for Decentralized Labs, Hospitals, Home Care,
Assisted Living Healthcare Facilities and Other End-Uses for
the Years 2012, 2020 & 2027

Table 109: Germany Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Application - Infectious
Diseases, Oncology, Hematology, Prenatal Testing and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 110: Germany Historic Review for Point of Care (POC)
Molecular Diagnostics by Application - Infectious Diseases,
Oncology, Hematology, Prenatal Testing and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 111: Germany 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Application - Percentage Breakdown of
Value Sales for Infectious Diseases, Oncology, Hematology,
Prenatal Testing and Other Applications for the Years 2012,
2020 & 2027

ITALY
Table 112: Italy Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 113: Italy Historic Review for Point of Care (POC)
Molecular Diagnostics by Technology - PCR-based, Genetic
Sequencing-based, Hybridization-based and Microarray-based
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 114: Italy 15-Year Perspective for Point of Care (POC)
Molecular Diagnostics by Technology - Percentage Breakdown of
Value Sales for PCR-based, Genetic Sequencing-based,
Hybridization-based and Microarray-based for the Years 2012,
2020 & 2027

Table 115: Italy Current & Future Analysis for Point of Care
(POC) Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 116: Italy Historic Review for Point of Care (POC)
Molecular Diagnostics by End-Use - Decentralized Labs,
Hospitals, Home Care, Assisted Living Healthcare Facilities and

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032550/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001